BMG

BMG Pharma is an Italian specialty pharmaceutical company that develops and patents innovative products in the areas of dermatology, oral care, ophthalmology, and aesthetics. The company utilizes proprietary technology platforms, such as Sigea, to chemically modify polymers and polysaccharides like hyaluronic acid to enhance their therapeutic properties. BMG Pharma follows a B2B business model, focusing on R&D and licensing its portfolio to international pharmaceutical partners for global distribution. Their lead products include treatments for oral mucositis and osteoarthritis, characterized by high safety profiles and targeted delivery mechanisms. The company's strategy involves leveraging its chemical expertise to create value-added versions of established molecules.